

**FOR IMMEDIATE RELEASE**

Company Name	Kyowa Kirin Co., Ltd.
Representative	Abdul Mullick, President and COO (Code No. 4151, Prime Market of TSE)
Inquiries	Hiroki Nakamura, Executive Vice President, Corporate Communications Department Media Contact: +81-3-5205-7205 Investor Contact: +81-3-5205-7206

## **Notice Regarding Kyowa Kirin Regaining Control of Rocatinlimab Development and Commercialization Program**

**TOKYO AND PRINCETON, Japan and the U.S., 30 January 2026** - Kyowa Kirin Co., Ltd. ("Kyowa Kirin") today announced that Kyowa Kirin and Amgen terminated the current rocatinlimab development and commercialization collaboration. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.

### **1. Outline and background of this matter**

Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. This business decision is the result of a strategic portfolio prioritization by Amgen.

Rocatinlimab's novel approach as an investigational, T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Kyowa Kirin and Amgen will initiate a smooth and orderly transition of the program, with the focus on ensuring continuity for participants currently enrolled in the clinical trial program. Amgen, which has partnered with Kyowa Kirin on numerous compounds over 41 years, will continue to manufacture rocatinlimab.

### **2. Future outlook**

Regulatory submission is planned for the first half of 2026. The administrative and financial impact of this matter will be disclosed in due course. The impact of this matter on the Company's business performance and financial condition is currently under review, and the earnings forecast incorporating these impacts is scheduled to be disclosed at the time of the announcement of the financial results for the fiscal year ended December 31, 2025, on February 9, 2026.

### **3. Schedule**

Date of contracts: January 30, 2026

End